{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T16:28:14Z","timestamp":1649003294855},"reference-count":28,"publisher":"LLC Obyedinennaya Redaktsiya","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ter. arkh."],"published-print":{"date-parts":[[2015]]},"DOI":"10.17116\/terarkh201587547-52","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T17:11:15Z","timestamp":1460653875000},"page":"47","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of intravenous methylprednisolone in the treatment of patients with active ankylosing spondylitis: Results of a 12-week, prospective, open-label, pilot (METALL) study"],"prefix":"10.26442","volume":"87","author":[{"given":"I. Z.","family":"Gaydukova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Rebrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Poddubnyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","reference":[{"key":"key-10.17116\/terarkh201587547-52-1","doi-asserted-by":"crossref","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007; 369(9570):1379-1390.","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"key-10.17116\/terarkh201587547-52-2","doi-asserted-by":"crossref","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904.","DOI":"10.1136\/ard.2011.151027"},{"key":"key-10.17116\/terarkh201587547-52-3","doi-asserted-by":"crossref","unstructured":"Peeters H, Vander Cruyssen B, Laukens D, Coucke P, Marichal D, Van Den Berghe M, Cuvelier C, Remaut E, Mielants H, De Keyser F, Vos MD. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn\u2019s disease. Ann Rheum Dis. 2004;63(9):1131-1134.","DOI":"10.1136\/ard.2004.021774"},{"key":"key-10.17116\/terarkh201587547-52-4","doi-asserted-by":"crossref","unstructured":"Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59(9):1270-1278.","DOI":"10.1002\/art.24001"},{"key":"key-10.17116\/terarkh201587547-52-5","doi-asserted-by":"crossref","unstructured":"Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67(3):346-352.","DOI":"10.1136\/ard.2007.078139"},{"key":"key-10.17116\/terarkh201587547-52-6","unstructured":"van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr; ATLAS Study Group. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2008;17:1272-1276."},{"key":"key-10.17116\/terarkh201587547-52-7","doi-asserted-by":"crossref","unstructured":"Haibel H, Fendler C, Listind J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of double-blind, randomised placebo-controlled short-term trial. Ann Rheum Dis. 2014;73:243-246.","DOI":"10.1136\/annrheumdis-2012-203055"},{"key":"key-10.17116\/terarkh201587547-52-8","unstructured":"Rumyantseva O.A., Bochkova A.G., Loginova E.Yu., Kiseleva N.M., Pushkova O.V., Bunchuk N.V. Vnutrivennoe primenenie vysokikh doz glyukokortikoidov u bol'nykh ankiloziruyushchim spondilitom. Terapevticheskii arkhiv. 2006;78(12):71-74."},{"key":"key-10.17116\/terarkh201587547-52-9","doi-asserted-by":"crossref","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.","DOI":"10.1002\/art.1780270401"},{"key":"key-10.17116\/terarkh201587547-52-10","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-2291."},{"key":"key-10.17116\/terarkh201587547-52-11","doi-asserted-by":"crossref","unstructured":"Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560-1567.","DOI":"10.1136\/ard.2007.072157"},{"key":"key-10.17116\/terarkh201587547-52-12","doi-asserted-by":"crossref","unstructured":"Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, K\u00f6hler L, Van Riel P, Vischer T, Bijlsma JW. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-722.","DOI":"10.1136\/ard.61.8.718"},{"key":"key-10.17116\/terarkh201587547-52-13","doi-asserted-by":"crossref","unstructured":"Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet. 2000;356(9224): 87-89.","DOI":"10.1016\/S0140-6736(00)02463-6"},{"key":"key-10.17116\/terarkh201587547-52-14","unstructured":"Richter MB, Woo P, Panayi GS, Trull A, Unger A, Shepherd P. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Immunol. 1983;53(1):51-59."},{"key":"key-10.17116\/terarkh201587547-52-15","doi-asserted-by":"crossref","unstructured":"Peters ND, Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol. 1992;21(3):134-138.","DOI":"10.3109\/03009749209095085"},{"key":"key-10.17116\/terarkh201587547-52-16","doi-asserted-by":"crossref","unstructured":"Mintz G, Enriquez RD, Mercado U, Robles EJ, Jimenez FJ, Gutierrez G. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum. 1981;24(5):734-736.","DOI":"10.1002\/art.1780240521"},{"key":"key-10.17116\/terarkh201587547-52-17","doi-asserted-by":"crossref","unstructured":"Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438-1444.","DOI":"10.1136\/ard.2003.016717"},{"key":"key-10.17116\/terarkh201587547-52-18","doi-asserted-by":"crossref","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876-1886.","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"key-10.17116\/terarkh201587547-52-19","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landew\u00e9 R; Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-1818.","DOI":"10.1136\/ard.2008.100826"},{"key":"key-10.17116\/terarkh201587547-52-20","doi-asserted-by":"crossref","unstructured":"Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, Kvien TK, Braun J, Baker D, van der Heijde D; Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2010;70(1):47-53.","DOI":"10.1136\/ard.2010.138594"},{"key":"key-10.17116\/terarkh201587547-52-21","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-2285."},{"key":"key-10.17116\/terarkh201587547-52-22","doi-asserted-by":"crossref","unstructured":"Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landew? R, van ver Tempel H, Mielants H, Dougados M, van der Heijde D. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62(2):127-132.","DOI":"10.1136\/ard.62.2.127"},{"key":"key-10.17116\/terarkh201587547-52-23","unstructured":"Rebrova O.Yu. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA. M.: Media-Sfera; 2002."},{"key":"key-10.17116\/terarkh201587547-52-24","doi-asserted-by":"crossref","unstructured":"Durez P, Malghem J, Nzeusseu Toukap A, Westhovens R, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007; 56(12):3919-3927.","DOI":"10.1002\/art.23055"},{"key":"key-10.17116\/terarkh201587547-52-25","unstructured":"Fendler C, Baraliakos X, Braun J. Glucocrticoid treatment in spondyloarthritis. Clin Exp Rheumatol. 2011;29(5 Suppl 8):S139-S142."},{"key":"key-10.17116\/terarkh201587547-52-26","unstructured":"Bochkova A.G. Rol' glyukokortikoidov v lechenii spondiloartritov. Sovremennaya revmatologiya. 2011;1:76-78."},{"key":"key-10.17116\/terarkh201587547-52-27","doi-asserted-by":"crossref","unstructured":"Keun Lee, Eun Young Lee, You-Sook Cho, Moon KA, Yoo B, Moon HB. Increased Expression of Glucocorticoid Receptor? Messenger RNA in Patients with Ankylosing Spondylitis. Korean J Int Med. 2005;20:146-151.","DOI":"10.3904\/kjim.2005.20.2.146"},{"key":"key-10.17116\/terarkh201587547-52-28","doi-asserted-by":"crossref","unstructured":"Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 2006;20(3):539-557.","DOI":"10.1016\/j.berh.2006.03.003"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T21:23:34Z","timestamp":1593379414000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/terapevticheskij-arkhiv\/2015\/5\/downloads\/ru\/490040-36602015056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"alternative-id":["terarkh201587547-52"],"URL":"https:\/\/doi.org\/10.17116\/terarkh201587547-52","relation":{},"ISSN":["0040-3660"],"issn-type":[{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}